251 related articles for article (PubMed ID: 34042015)
1. Pembrolizumab for the treatment of renal cell carcinoma.
Di Bona C; Stühler V; Rausch S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Sep; 21(9):1157-1164. PubMed ID: 34042015
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
[No Abstract] [Full Text] [Related]
3. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma.
Ged Y; Lee CH
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1049-1059. PubMed ID: 36154355
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.
Capitanio U; Fallara G; Raggi D; Nocera L; Larcher A; Belladelli F; Rowe I; Briganti A; Salonia A; Karakiewicz P; Montorsi F; Martini A; Necchi A
Curr Probl Cancer; 2022 Aug; 46(4):100875. PubMed ID: 35679628
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibition for the treatment of renal cell carcinoma.
Stühler V; Maas JM; Rausch S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2020 Jan; 20(1):83-94. PubMed ID: 31587590
[No Abstract] [Full Text] [Related]
8. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population.
Fujiwara R; Yuasa T; Kobayashi K; Yoshida T; Kageyama S
Expert Rev Anticancer Ther; 2023 May; 23(5):461-469. PubMed ID: 37038721
[TBL] [Abstract][Full Text] [Related]
10. [Risk-adapted therapy for metastatic renal cell carcinoma].
Grimm MO; Leucht K; Foller S; Grünwald V
Urologe A; 2020 Feb; 59(2):155-161. PubMed ID: 32006060
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
12. Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach.
Wood LS; Ornstein MC
JCO Oncol Pract; 2020 Feb; 16(2_suppl):15s-19s. PubMed ID: 32045538
[TBL] [Abstract][Full Text] [Related]
13. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
Soleimani M; Nappi L; Kollmannsberger C
Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
[TBL] [Abstract][Full Text] [Related]
14. An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma.
Marchetti A; Rosellini M; Rizzo A; Mollica V; Battelli N; Massari F; Santoni M
Expert Opin Pharmacother; 2021 Dec; 22(17):2323-2336. PubMed ID: 34405738
[No Abstract] [Full Text] [Related]
15. Recent pharmacological approaches for the treatment of renal cell carcinoma.
Alimohammadi A; Fajkovic H; Remzi M; Shariat S; Schmidinger M
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):187-195. PubMed ID: 35285369
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
[No Abstract] [Full Text] [Related]
17. An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma.
Rosellini M; Tassinari E; Marchetti A; Tateo V; Nuvola G; Rizzo A; Massari F; Mollica V
Expert Opin Drug Saf; 2023 Apr; 22(4):279-291. PubMed ID: 37055875
[TBL] [Abstract][Full Text] [Related]
18. The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.
Jacob A; Shook J; Hutson T
Expert Rev Anticancer Ther; 2021 Apr; 21(4):365-372. PubMed ID: 33393393
[No Abstract] [Full Text] [Related]
19. Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy.
Leslie I; Boos LA; Larkin J; Pickering L
Expert Rev Anticancer Ther; 2020 May; 20(5):343-354. PubMed ID: 32293937
[No Abstract] [Full Text] [Related]
20. Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab.
Serzan M; Atkins MB
Expert Rev Anticancer Ther; 2022 Jun; 22(6):565-574. PubMed ID: 35483033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
